Who are Baricitinib Oral Tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Leqselvi, JAK Inhibitor, Janus Kinase Inhibitor, Delgocitinib cream, Pf-07293893, Xeljanz.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/baricitinib-oral-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Baricitinib Oral Tablet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Baricitinib Oral Tablet (Baricitinib Oral Tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK inhibitor. Area: Immunology.

phase 3 JAK inhibitor JAK1, JAK2 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Baricitinib Oral Tablet (Baricitinib Oral Tablet) — Azienda Ospedaliero, Universitaria Pisana. Baricitinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Baricitinib Oral Tablet TARGET	Baricitinib Oral Tablet	Azienda Ospedaliero, Universitaria Pisana	phase 3	JAK inhibitor	JAK1, JAK2
Leqselvi	DEURUXOLITINIB	Sun Pharm Inds Inc	marketed		JAK1, JAK2, TYK2	2024-01-01
JAK Inhibitor	JAK Inhibitor	Fred Hutchinson Cancer Center	marketed	JAK inhibitor	JAK1, JAK2, JAK3, and/or TYK2
Janus Kinase Inhibitor	Janus Kinase Inhibitor	Peking Union Medical College Hospital	marketed	Janus Kinase Inhibitor	JAK1, JAK2, JAK3, TYK2
Delgocitinib cream	Delgocitinib cream	LEO Pharma	phase 3	JAK inhibitor	JAK1, JAK2, JAK3, TYK2
Pf-07293893	pf-07293893	Pfizer	marketed	JAK inhibitor	Janus kinase (JAK) pathway	Not available
Xeljanz	Tofacitinib Citrate	Pfizer	marketed	JAK inhibitor	Janus kinase (JAK) enzymes	2012-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK inhibitor class)

Pfizer · 19 drugs in this class
Aclaris Therapeutics, Inc. · 2 drugs in this class
Beijing Friendship Hospital · 2 drugs in this class
Azienda Ospedaliero, Universitaria Pisana · 1 drug in this class
CAGE Bio Inc. · 1 drug in this class
CTI BioPharma · 1 drug in this class
Celgene · 1 drug in this class
Fred Hutchinson Cancer Center · 1 drug in this class
LEO Pharma · 1 drug in this class
McMaster University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Baricitinib Oral Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/baricitinib-oral-tablet. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab